HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on CARISMA Therapeutics (NASDAQ:CARM) and raises the price target from $10 to $11.
August 11, 2023 | 11:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a 'Buy' rating on CARISMA Therapeutics and raises the price target from $10 to $11, which could positively impact the stock in the short term.
The raised price target by HC Wainwright & Co. indicates a positive outlook for CARISMA Therapeutics. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100